[Translation] A multicenter, randomized, double-blind, levofloxacin-controlled phase III clinical study to evaluate the efficacy and safety of nemofloxacin malate capsules in the treatment of simple urinary tract infection

以左氧氟沙星片为阳性对照，评价苹果酸奈诺沙星胶囊治疗单纯性尿路感染的临床、微生物疗效、安全性，了解单纯性尿路感染患者连续口服苹果酸奈诺沙星的群体药代动力学（PPK）特征及进行药代动力学（PK）/药效学（PD）分析，评价给药方案。

[Translation]

To evaluate the clinical, microbiological efficacy and safety of nemofloxacin malate capsules in the treatment of uncomplicated urinary tract infection using levofloxacin tablets as a positive control, to understand the population pharmacokinetic (PPK) characteristics of continuous oral administration of nemofloxacin malate in patients with uncomplicated urinary tract infection, to conduct pharmacokinetic (PK)/pharmacodynamic (PD) analysis and to evaluate the dosing regimen.

Start Date29 Aug 2023

Sponsor / Collaborator

Zhejiang Pharmaceutical Co. Ltd. Xinchang Pharmaceutical Factory

CTR20181341 / CompletedPhase 4

评价口服苹果酸奈诺沙星（Nemonoxacin）治疗成人社区获得性肺炎患者的有效性和安全性的多中心Ⅳ期临床研究

[Translation] A multicenter phase IV clinical study to evaluate the efficacy and safety of oral nemonoxacin malate in the treatment of adult patients with community-acquired pneumonia

评价口服苹果酸奈诺沙星治疗成人社区获得性肺炎的临床和微生物学疗效以及安全性，同时了解成人社区获得性肺炎患者连续口服苹果酸奈诺沙星的群体药代动力学（PPK）特征及评价药代动力学（PK）/药效学（PD）分析结果。

[Translation]

To evaluate the clinical and microbiological efficacy and safety of oral nemonoxacin malate in the treatment of community-acquired pneumonia in adults, and to understand the population pharmacokinetic (PPK) characteristics of continuous oral nemonoxacin malate in adult patients with community-acquired pneumonia and evaluate the results of pharmacokinetic (PK)/pharmacodynamic (PD) analysis.

Start Date26 Nov 2018

Sponsor / Collaborator

Taigen Biopharmaceuticals Co. (Beijing), Ltd.

[+1]

NCT05133752 / CompletedPhase 4

A Multi-Center, Open-Label, Single-Arm, Phase IV Study to Evaluate the Safety and Clinical Efficacy of Oral Administration With Nemonoxacin in Treating Elderly Patients With Community-Acquired Pneumonia

This study was to evaluate the safety and efficacy of oral nemonoxacin in treating elderly patients (aged ≥ 65 years) with community-acquired pneumonia (CAP).

Start Date11 Sep 2018

Sponsor / Collaborator

TaiGen Biotechnology Co., Ltd.

100 Clinical Results associated with Nemonoxacin Malate

100 Translational Medicine associated with Nemonoxacin Malate

100 Patents (Medical) associated with Nemonoxacin Malate

Literatures (Medical) associated with Nemonoxacin Malate

01 Aug 2024·INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients

Article

Author: Li, Xiangyang ; Zhu, Yingqun ; Sun, Shenghua ; Li, Ying ; Mo, Biwen ; Xu, Xingxiang ; Liu, Hua ; Wang, Xuefen ; Xu, Jinfu ; Yang, Yanping ; Yang, Hongzhong ; Huang, Huaping ; Chang, Xiaoyue ; Kuang, Jiulong ; Chen, Zhang ; Qin, Zhiqiang ; Xiao, Zuke ; Zhu, Guangfa ; Tong, Zhaohui ; Lv, Xiaoju ; Peng, Liping ; Wu, Shiman ; Liu, Deling ; Huang, Yijiang ; Zhang, Yingyuan ; Wang, Kai ; Lu, Youjin ; Jin, Faguang ; Ye, Feng ; He, Yong ; Wang, Wei ; Fu, Xiuhua ; Wang, Ying ; Cao, Zhaolong ; Zhang, Min ; Liang, Yongjie ; Hui, Fuxin ; Zhao, Li ; Zhu, Demei ; Ma, Zhuang ; Qiu, Chen ; Ying, Kejing ; Li, Chen ; Chen, Jichao ; Lv, Yuan

BACKGROUND:

Nemonoxacin malate is a novel non-fluorinated quinolone for oral and intravenous (IV) administration. This phase 3, multicentre, randomised, double-blind, double-dummy, parallel-controlled clinical trial (NCT02205112) evaluated the efficacy and safety of IV nemonoxacin vs. levofloxacin for the treatment of community-acquired pneumonia (CAP) in adult patients.

METHODS:

Eligible patients were randomised to receive 500 mg nemonoxacin or levofloxacin via IV infusion, once daily for 7-14 days. The primary endpoint was the clinical cure rate at the test-of-cure (TOC) visit in the modified intent-to-treat (mITT) population. Secondary efficacy and safety were also compared between nemonoxacin and levofloxacin.

RESULTS:

Overall, 525 patients were randomised and treated with nemonoxacin (n = 349) or levofloxacin (n = 176). The clinical cure rate was 91.8% (279/304) for nemonoxacin and 85.7% (138/161) for levofloxacin in the mITT population (P > 0.05). The clinical efficacy of nemonoxacin was non-inferior to levofloxacin for treatment of CAP. Microbiological success rate with nemonoxacin was 88.8% (95/107) and with levofloxacin was 87.8% (43/49) (P > 0.05) at the TOC visit in the bacteriological mITT population. The incidence of drug-related adverse events (AEs) was 37.1% in the nemonoxacin group and 22.2% in the levofloxacin group. These AEs were mostly local reactions at the infusion site, nausea, elevated alanine aminotransferase/aspartate aminotransferase (ALT/AST), and QT interval prolongation. The nemonoxacin-related AEs were mostly mild and resolved after discontinuation of nemonoxacin.

CONCLUSIONS:

Nemonoxacin 500 mg IV once daily for 7-14 days is effective and safe and non-inferior to levofloxacin for treating CAP in adult patients.

01 Jun 2024·CLINICAL PHARMACOKINETICS

Together or Apart? Revealing the Impact of Dietary Interventions on Bioavailability of Quinolones: A Systematic Review with Meta-analyses

Review

Author: Wiesner, Agnieszka ; Gawalska, Alicja ; Paśko, Paweł ; Zagrodzki, Paweł

BACKGROUND AND OBJECTIVE:

Managing drug-food interactions is essential for optimizing the effectiveness and safety profile of quinolones. Following PRISMA guidelines, we systematically reviewed the influence of dietary interventions on the bioavailability of 22 quinolones.

METHODS:

All studies describing or investigating the impact of food, beverages, antacids, and mineral supplements on pharmacokinetic parameters or pharmacokinetic/pharmacodynamic indices of orally taken quinolones were considered for inclusion. We excluded reviews, in vitro and in silico studies, studies performed on animals, and those involving alcohol. We performed the search in Medline (via PubMed), Embase, and Cochrane Library, covering reports from database inception to December 2022. We used the following tools to assess the risk of bias: version 2 of the Cochrane risk-of-bias tool for parallel trials, the Cochrane risk-of-bias tool for cross-over studies, and the NIH quality assessment tool for before-after studies. We performed quantitative analyses for each quinolone if two or more food-effect studies with specified and comparable study designs were available. If meta-analyses were not applicable, we qualitatively summarized the results.

RESULTS:

We included 109 studies from 101 reports. Meta-analyses were conducted for 12 antibiotics and qualitative synthesis was employed for the remaining drugs. Of the studies, 60.5% were open-label, cross-over, as recommended by FDA. We judged 46% of studies as having a high risk of bias and only 4% of having a low risk of bias. Among 19 quinolones with available food impact data, 14 (74%) had potentially clinically important interactions. For nalidixic acid, oxolinic acid, and tosufloxacin, food exerted a high positive impact on bioavailability (AUC or C_max increased by > 45%), whereas, for all the remaining drugs, postprandial absorption was lower. The most significant negative influence of food (AUC or C_max decreased by > 40%) occurred for delafloxacin capsules and norfloxacin, whereas the moderate influence (AUC or C_max decreased by 30-40%) occurred for nemonoxacin and rufloxacin. All 14 analysed quinolones showed a substantial reduction in bioavailability when co-administered with antacids and mineral supplements, except for calcium preparations. The impact of beverages was evaluated for 10 quinolones, with 50% experiencing significantly reduced absorption in the presence of milk (the highest negative impact for ciprofloxacin). Moreover, both ciprofloxacin and levofloxacin demonstrated compromised bioavailability when consumed with orange juice, particularly calcium-fortified.

DISCUSSION:

Several factors may influence interactions, including the physicochemical characteristics of quinolones, the type of intervention, drug formulation, and the patient's health status. We assessed the quality of evidence as low due to the poor actuality of included studies, their methodological diversity, and uneven data availability for individual drugs.

01 May 2024·Journal of general internal medicine

Identifying the Best Initial Oral Antibiotics for Adults with Community-Acquired Pneumonia: A Network Meta-Analysis

Review

Author: Ebell, Mark H ; Kurotschka, Peter K ; Hulme, Cassie ; Bentivegna, Michelle

BACKGROUND:

The objective of this network meta-analysis was to compare rates of clinical response and mortality for empiric oral antibiotic regimens in adults with mild-moderate community-acquired pneumonia (CAP).

METHODS:

We searched PubMed, Cochrane, and the reference lists of systematic reviews and clinical guidelines. We included randomized trials of adults with radiologically confirmed mild to moderate CAP initially treated orally and reporting clinical cure or mortality. Abstracts and studies were reviewed in parallel for inclusion in the analysis and for data abstraction. We performed separate analyses by antibiotic medications and antibiotic classes and present the results through network diagrams and forest plots sorted by p-scores. We assessed the quality of each study using the Cochrane Risk of Bias framework, as well as global and local inconsistency.

RESULTS:

We identified 24 studies with 9361 patients: six at low risk of bias, six at unclear risk, and 12 at high risk. Nemonoxacin, levofloxacin, and telithromycin were most likely to achieve clinical response (p-score 0.79, 0.71, and 0.69 respectively), while penicillin and amoxicillin were least likely to achieve clinical response. Levofloxacin, nemonoxacin, azithromycin, and amoxicillin-clavulanate were most likely to be associated with lower mortality (p-score 0.85, 0.75, 0.74, and 0.68 respectively). By antibiotic class, quinolones and macrolides were most effective for clinical response (0.71 and 0.70 respectively), with amoxicillin-clavulanate plus macrolides and beta-lactams being less effective (p-score 0.11 and 0.22). Quinolones were most likely to be associated with lower mortality (0.63). All confidence intervals were broad and partially overlapping.

CONCLUSION:

We observed trends toward a better clinical response and lower mortality for quinolones as empiric antibiotics for CAP, but found no conclusive evidence of any antibiotic being clearly more effective than another. More trials are needed to inform guideline recommendations on the most effective antibiotic regimens for outpatients with mild to moderate CAP.

News (Medical) associated with Nemonoxacin Malate

18 Apr 2024

·www.prnewswire.com

TaiGen Successfully Completes TG-1000 Phase III Study

TAIPEI, April 17, 2024 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announces today that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to alleviation of all influenza symptoms after TG-1000 treatment was shorter than that of the placebo group, with a statistically significant difference. TG-1000 also possesses great safety profile, and there was no clinically significant safety concerns observed. Furthermore, TaiGen will advance cooperation and development negotiation in Europe, the U.S., and other Asian countries. It is expected that in the second half of the year, Joincare Pharmaceutical will file a new drug application for TG-1000 in mainland China. The primary endpoint of the study, the median time to alleviation of all influence symptoms of TG-1000 group (60.9 hours), was shorter than that of the placebo group (87.9 hours). It shows that TG-1000 effectively shortens the time for influenza symptom alleviation, which is statistically significant (P<0.0001). The secondary endpoints of the study include antiviral efficacy, clinical symptom alleviation, and influenza related complications. Those indicators are still undergoing testing and statistical analysis. The incidence rate of adverse effect (AE) of TG-1000 group is similar to that of placebo group. TG-1000 treatment group possesses favorable safety profile with no death or serious adverse reaction occurred. The phase III trial of TG-1000 is a multi-center, randomized and double-blinded study. The purpose is to evaluate the efficacy and safety of TG-1000 compared with placebo in adult and adolescent patients with uncomplicated acute influenza infection. 752 participants are randomly allocated to TG-1000 treatment group and placebo control group. Consistent with China influenza surveillance data, the majority of patients admitted to the Phase III trial are influenza virus A infected. Kuo-Lung Huang, Chairman and CEO of TaiGen commented on the trial results, stating that "The surge in influenza cases from 2023 to 2024 indicates the trend of coexistence between influenza viruses and humans. The positive outcome of TG-1000 Phase III trial represents another opportunity for an innovative drug to enter clinical use. TaiGen holds a cautiously optimistic attitude." He mentioned that the sales of influenza medication in mainland China exceeded RMB 6 billion in 2023, returning to the market size before the COVID-19 epidemic. The potential market size for innovative flu medication in the future can be expected. About TaiGen Biotechnology TaiGen Biotechnology, with a subsidiary in Beijing, China, was founded in 2001 and became listed on the Taiwan OTC Stock Market in 2014. TaiGen is a fully-integrated pharmaceutical company dedicated to the development of innovative small molecule drugs with a focus on anti-infective drug research. Its flagship product, non-fluorinated quinolone antibiotic Taigexyn® (Nemonoxacin), has obtained marketing approvals in Taiwan, mainland China, and Russia. The influenza antiviral TG-1000 has completed the phase III clinical trial. SOURCE TaiGen

Phase 3Drug Approval

24 May 2021

·www.globenewswire.com

Acute Bacterial Skin and Skin Structure Infections Pipeline Featuring Plethora of Emerging Drugs, Key Companies

Los Angeles, USA, May 24, 2021 (GLOBE NEWSWIRE) -- Acute Bacterial Skin and Skin Structure Infections Pipeline Featuring Plethora of Emerging Drugs, Key Companies Ceftobiprole Medocaril under Phase III trials is expected to turn out to be the most effective treatment of Acute Bacterial Skin and Skin Structure Infections. DelveInsight’s ‘Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Pipeline Insights’ report offers a detailed picture of the ABSSSI emerging therapies expected to enter the Acute Bacterial Skin and Skin Structure Infections market along with detailed coverage of the pipeline therapies under development in pre-clinical as well as clinical stages of development, partnerships taking place in the domain, recent happenings in space and growth prospects across the Diabetes domain. Some of the key highlights of the ABSSSI Pipeline report: Request for Sample to know more about the therapies that are set to grab maximum patient pool @ ABSSSI Emerging Therapies and Forecast Acute Bacterial Skin and Skin Structure Infection is a bacterial infection of the skin and associated tissues. The FDA defines skin and skin structure infections as an acute bacterial skin and skin structure infection or ABSSSI if the infection is accompanied by redness, edema, and/or induration of a minimum surface area of 75 cm2, accompanied by lymph node enlargement or systemic symptoms such as fever ≥38°C (100.4°F). Some of the most common bacterial pathogens that cause Acute Bacterial Skin and Skin Structure Infections are Streptococcus pyogenes and Staphylococcus aureus, including methicillin-resistant S.aureus. Less common causes include other Streptococcus species, Enterococcus faecalis, or Gram Negative bacteria. The severity of Acute Bacterial Skin and Skin Structure Infections has led to an increasing emphasis on the identification of novel strategies to treat this disease. For more information on emerging drugs, visit Acute Bacterial Skin and Skin Structure Infections Pipeline Analysis ABSSSI Pipeline Drugs Request for Sample to know more @ Acute Bacterial Skin and Skin Structure Infections Pipeline Analysis, Key Companies and Futuristic Trends Acute Bacterial Skin and Skin Structure Infections Drugs and Therapeutic Assessment The ABSSSI Pipeline report presents comprehensive insights into active ABSSSI pipeline assets segmented by Stage, ABSSSI Product Type, Route of Administration, Molecule Type, Target, and Indications of various drugs. By Product Type By Stage By Molecule Type By Route of Administration By Mechanism of Action By Targets By Stage and Route of AdministrationBy Stage and Product Type Reach out for Rich and Deep Market Assessment and Consulting Solutions Scope of the Report Coverage: GlobalKey Players: Basilea Pharmaceutica, TenNor Therapeutics, Innovation Pharmaceuticals, Debiopharm Group, MicuRx Pharmaceuticals, Taxis Pharmaceuticals, Botanix pharmaceuticals, Motif Bio, KBP Biosciences, Atox Bio and others. Key ABSSSI Pipeline Therapies: Ceftobiprole medocaril, TNP-2092, Brilacidin, Afabicin, Contezolid acefosamil, TXA709, Cannabidiol, KBP-7072, Nemonoxacin, AB-103 and others. Reach out @ Acute Bacterial Skin and Skin Structure Infections Pipeline: Novel therapies and emerging technologies Table of Contents Visit to know more of what’s covered @ ABSSSI Emerging Therapies Related ReportsAcute Bacterial Skin And Skin Structure Infections MarketDelveInsight's "Acute Bacterial Skin and Skin Structure Infections - Market Insights, Epidemiology, and Market Forecast-2030" report. Acne Vulgaris MarketDelveInsight's "Acne Vulgaris Market Insights, Epidemiology, and Market Forecast-2030" report. Moderate To Severe Atopic Dermatitis MarketDelveInsight's "Moderate to Severe Atopic Dermatitis (AD) - Market Insights, Epidemiology, and Market Forecast-2030" report. Acral Lentiginous Melanoma MarketDelveInsight's "Acral lentiginous melanoma - Market Insights, Epidemiology, and Market Forecast-2030" report. Androgenetic Alopecia MarketDelveInsight's "Androgenetic Alopecia Market Insights, Epidemiology, and Market Forecast-2030" report. Related Posts ABSSSI Market and Key Treatments Atopic Dermatitis MarketRosacea Pipeline and Therapies Marijuana Clinical TrialsOpiate Withdrawal Cocktail About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News

18 Mar 2015

·www.biospace.com

TaiGen Biotechnology Announces Burixafor Collaboration With Celldex And The University Hospital Carl Gustav Carus Dresden In Germany

TAIPEI, March 18, 2015 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today announced the signing of an agreement to collaborate with Cellex GmbH and the University Hospital Carl Gustav Carus Dresden in Germany in an investigator-initiated clinical trial using burixafor in stem cell mobilization in healthy donors. The study titled "Burixafor in allogeneic poor mobilizers" is a Phase 2 open-label study to determine the effect of a single dose of burixafor in up to 37 poor mobilizers. The rate of donation success will be measured as the primary endpoint. Under the terms of the agreement, Cellex will be responsible for obtaining clinical trial approval and conduct of the trial and assume all associated costs. TaiGen will have the option to obtain and use the data for future development and filing of market authorization. Professor Gerhard Ehninger, founder of Cellex and Chair of the Department of Hematology at the University Hospital commented, "We learned of burixafor at the 2013 American Society of Hematology meeting and were impressed with its efficacy in autologous transplantation. Currently approximately 5% of allogeneic donors fail to mobilize enough CD34+ cells to reach an optimal dose for transplantation using G-CSF. Patients receiving transplants with suboptimal CD34+ doses are at risk for delayed or incomplete engraftment and increased rate of infections. The stem cell mobilization activity of burixafor will be highly desirable in increasing CD34+ cell yields in poor mobilizing donors." Dr. Ming-Chu Hsu, Chairman and CEO of TaiGen said, "We are delighted to work with Professor Ehninger, an experienced hematologist and key opinion leader. From our clinical study to date, we know that burixafor has excellent activity and safety in healthy volunteers and cancer patients. With Cellex as our partner we have access to a larger donor population and study its effect on donors who failed G-CSF. This collaboration with Professor Ehninger and Cellex enabled TaiGen to explore additional indications and increase the market potential of TG-0054." About Cellex GmbH Cellex, founded by Professor Ehninger in 2001, is the largest stem cell collection center in Germany and one of the largest in Europe. The two sites of Cellex in Dresden and Cologne together performed over 3,000 stem cell collections in 2014 and are serving donors and patients worldwide. About Burixafor Burixafor, also known as TG-0054, is a novel, potent and selective chemokine receptor antagonist discovered by TaiGen. Burixafor rapidly mobilizes stem cells and progenitor cells from the bone marrow into peripheral circulation. Burixafor is currently in Phase 2 study in autologous stem cell transplantation in the US. Another Phase 2 study in chemosensitization is planned for China in 2015. Other potential indications also include regenerative medicine and ischemic diseases. About TaiGen Biotechnology TaiGen Biotechnology is a leading research-based and product-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, China. In addition to TG-0054, TaiGen has two other NCEs in product portfolio: Nemonoxacin (oral formulation) has received NDA approval from Taiwan FDA and pending approval from China FDA; and TG-2349 is a pan-genotypic NS3/4A protease inhibitor currently in Phase 2. For more information please contact: Peter W. Tsao, PhD, Vice President of Business Development Tel: +886-2-8177-7072 ptsao@taigenbiotech.com.twTo view the original version on PR Newswire, visit: SOURCE Taigen Biotechnology Help employers find you! Check out all the jobs and post your resume.

Collaborate

100 Deals associated with Nemonoxacin Malate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Nemonoxacin Malate	J01MB08	DB06600

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Community Acquired Pneumonia	CN	Zhejiang Pharmaceutical Co. Ltd. Xinchang Pharmaceutical Factory	27 May 2016

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Infectious Diseases	NDA/BLA	RU	R-Pharm Overseas, Inc.	30 Jan 2022
Urinary Tract Infections	Phase 3	CN	Zhejiang Pharmaceutical Co. Ltd. Xinchang Pharmaceutical Factory	29 Aug 2023
Pneumonia, Bacterial	Phase 3	RU	R-Pharm JSC	04 May 2016
Cataract Anterior Polar Dominant	Phase 3	CN	TaiGen Biotechnology Co., Ltd.	01 Apr 2011
Cataract Anterior Polar Dominant	Phase 3	TW	TaiGen Biotechnology Co., Ltd.	01 Apr 2011
Diabetic foot infection	Phase 2	US	TaiGen Biotechnology Co., Ltd.	01 Jun 2008
Diabetic foot infection	Phase 2	ZA	TaiGen Biotechnology Co., Ltd.	01 Jun 2008
Diabetic foot infection	Phase 2	TW	TaiGen Biotechnology Co., Ltd.	01 Jun 2008
Diabetic foot infection	Phase 2	TH	TaiGen Biotechnology Co., Ltd.	01 Jun 2008
Functional disorder	Phase 1	CN	Zhejiang Medicine Co., Ltd.	05 Apr 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03551210 (CTgov)	Phase 3	Pneumonia, Bacterial \| Community Acquired Pneumonia	342	Placebo (100 ml)+Nemonoxacin (Nemonoxacin)	gszhqrjvef(omtyvkjypa): Difference in percentage = 6.1 (95% CI, -0.7 to 13.0); Odds Ratio (OR) = 1.45 (95% CI, 0.49 - 4.29), P-Value = 0.499 View more	-	16 Feb 2023
				Placebo (250 ml)+Tavanic (Tavanic®)
NCT02604498 (Pubmed)	Phase 1	Liver Injury	10	Nemonoxacin (Moderate Hepatic Impairment Group)	wxxxfdgxwt(iisoevksml) = mvvkswayyw afycvszwvk (tqbtwmetvc, (17.30))	-	01 Mar 2019
				Nemonoxacin (Healthy Control Group)	wxxxfdgxwt(iisoevksml) = vskpowkxqg afycvszwvk (tqbtwmetvc, (10.16))
NCT01529476 (Pubmed \| J Microbiol Immunol Infect)	Phase 3	Community Acquired Pneumonia	527	Nemonoxacin 500 mg	eokzubvbou(ybycmjysdw) = The incidence of adverse events (AEs) was comparable between nemonoxacin (33.1%, 118/356) and levofloxacin (33.3%, 57/171) crkytkysvg (gsqzqilaba )	Positive	01 Feb 2019
				Levofloxacin 500 mg
NCT01537250 (Pubmed \| J Microbiol Immunol Infect)	Phase 2	Community Acquired Pneumonia	192	Nemonoxacin 500 mg	gikddzahwv(saalvobkyn) = Most drug-related adverse events were mild and transient, mainly gastrointestinal symptoms such as nausea and vomiting, transient neutropenia, and elevated liver enzymes tfvemoqhpj (jovqfczuty ) View more	Positive	01 Dec 2017
				Nemonoxacin 750 mg
NCT01944774 (Pubmed \| Antimicrob Agents Chemother)	Phase 2	-	207	500 mg nemonoxacin	fonyyegdnr(gpzrdapfoz) = liddddvmct skucbckdvr (dliceiijzr ) View more	-	01 Mar 2015
				650 mg nemonoxacin	fonyyegdnr(gpzrdapfoz) = sjdodvvwre skucbckdvr (dliceiijzr ) View more
NCT01944774 (CTgov)	Phase 2	Community Acquired Pneumonia	207	Nemonoxacin 500 mg (Nemonoxacin 500 mg)	rxfcqqbewy(kzpxyuomxw) = rfjnkgwlst cpmbrzcnfs (vrgculddki, zyujnpagkb - csiequtpcy) View more	-	18 Feb 2015
				Nemonoxacin 650 mg (Nemonoxacin 650 mg)	rxfcqqbewy(kzpxyuomxw) = rtgihlscxt cpmbrzcnfs (vrgculddki, kpvlhtkvta - dxmnethazk) View more
NCT01944774 (Pubmed \| Antimicrob Agents Chemother)	Phase 2	-	92	Intravenous nemonoxacin	xvfilddcuc(pexywlcfkd) = qtjdjtngsw kkvarnzpli (bumknqkygk ) View more	-	01 Oct 2014

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis